Imiquimod treatment for lentigo maligna – LIMIT-1 trial

We read with interest the methods and results of the LIMIT-1 trial regarding primary imiquimod treatment for lentigo maligna (LM) in the journal.¹ We applaud the authors for using histopathology from a resective specimen as the reference standard.

This article is protected by copyright. All rights reserved.

http://ift.tt/2o78Ccp